Zinc-oxaprozin compounds: Synthesis, structure and biological activity

Marialena Lazou,Antonios G Hatzidimitriou,Athanasios N Papadopoulos,George Psomas
DOI: https://doi.org/10.1016/j.jinorgbio.2019.03.016
Abstract:Four novel zinc complexes, namely [Zn(oxa)2(MeOH)4] (1), [Zn(oxa)2(H2O)(bipy)]·MeOH·2.5H2O (2·MeOH·2.5H2O), [Zn(oxa)2(bipyam)]·1.25MeOH (3·1.25MeOH) and [Zn(oxa)2(phen)] (4), with the non-steroidal anti-inflammatory drug oxaprozin (Hoxa) and a N,N'-donor heterocyclic ligand, such as 2,2'‑bipyridylamine (bipyam), 1,10‑phenanthroline (phen) or 2,2'‑bipyridine (bipy), were characterized with physicochemical techniques, various spectroscopies and single-crystal X-ray crystallography. In these coordination compounds, the oxaprozin ligands are coordinated to zinc ion in a monodentate or a bidentate chelating binding mode. The antioxidant activity of the complexes was evaluated via their ability to scavenge in vitro 1,1‑diphenyl‑2‑picrylhydrazyl, hydroxyl and 2,2'‑azinobis‑(3‑ethylbenzothiazoline‑6‑sulfonic acid) radicals. The complexes bind to calf-thymus DNA via intercalation as suggested via a series of studies employing UV-vis spectroscopy, DNA-viscosity measurements and competition with ethidium bromide. The complexes may bind to serum albumins tightly and reversibly in order to get transferred through the bloodstream.
What problem does this paper attempt to address?